

**SUPPLEMENTARY TABLE S4: UNIVARIATE AND MULTIVARIATE HAZARD RATIOS FOR PRE-DIAGNOSIS AND DE NOVO POST-DIAGNOSIS METFORMIN EXPOSURE AND MORTALITY; DIABETIC SUBGROUP, STAGES I-III COLORECTAL CANCER.**

Exposure Information			Colorectal cancer-specific survival			Overall survival		
Exposure	N (N=301)	Person -years	Deaths (Crude Rate) <sup>a</sup>	Univariate HR (95% CI)	Adjusted HR (95% CI) <sup>b</sup>	Deaths (Crude Rate) <sup>a</sup>	Univariate HR (95% CI)	Adjusted HR (95% CI) <sup>b</sup>
No metformin <sup>c</sup>	89	332	20 (60)	(Ref)	(Ref)	48 (145)	(Ref)	(Ref)
Metformin post-diagnosis only <sup>d</sup>	42	173	9 (52)	0.88 (0.40-1.92)	1.10 (0.47-2.56)	18 (104)	0.73 (0.43-1.26)	0.98 (0.55-1.76)
Metformin pre-diagnosis <sup>e</sup>	170	648	37 (57)	0.92 (0.54-1.59)	0.92 (0.52-1.64)	85 (131)	0.92 (0.64-1.30)	0.93 (0.64-1.36)

- a) Rate calculated as deaths per 1000 person-years. Survival time calculated from 365 days after cancer diagnosis until death or end of follow up.
- b) Adjusted for age, tumour stage, tumour grade, year of diagnosis, comorbidity score, aspirin use, exposure to non-metformin ADDs (sulfonylureas yes/no, insulin yes/no, other ADDs yes/no).
- c) Received anti-diabetic medication other than metformin during the year prior to cancer diagnosis or the year post cancer diagnosis.
- d) Received metformin in the year post cancer diagnosis but not in the year prior to cancer diagnosis.
- e) Received metformin in the year prior to cancer diagnosis.